The prognostic value of pretreatment of systemic inflammatory responses in patients with urothelial carcinoma undergoing radical cystectomy

被引:59
作者
Ku, J. H. [1 ]
Kang, M. [1 ]
Kim, H. S. [1 ]
Jeong, C. W. [1 ]
Kwak, C. [1 ]
Kim, H. H. [1 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Urol, Seoul 151, South Korea
关键词
bladder cancer; cystectomy; urothelial carcinoma; inflammation; prognosis; C-REACTIVE PROTEIN; CANCER-SPECIFIC MORTALITY; TO-LYMPHOCYTE RATIO; CELL LUNG-CANCER; PREDICTS SURVIVAL; BLADDER-CANCER; NEUTROPHIL; MODELS; TUMOR; CHEMOTHERAPY;
D O I
10.1038/bjc.2014.631
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Systemic inflammatory response (SIR) is important in the relationship between the tumour, the host, and outcome in cancer patients. However, limited data exist regarding the prognostic significance of SIR in bladder cancer. We investigate the utility of pretreatment SIR in patients with urothelial carcinoma undergoing radical cystectomy. Methods: The study cohort consisted of 419 patients with a median follow-up of 37.7 months. The SIRs used for each described prognostic nomogram are consistent with previously published data: C-reactive protein, albumin, white cell count, neutrophil count, lymphocyte count, and platelet count. Primary end point was disease-specific survival (DSS) and overall survival (OS) after surgery. Cox regression models were used to determine the time to disease-specific and overall mortality. Multivariate regression coefficients of the predictors were used to develop nomograms for predicting 5-year DSS and OS probability. Results: Multivariate Cox regression analyses revealed that albumin, lymphocyte count, and platelet count were significantly associated with a significantly increased risk for death from bladder cancer. The nomograms including each index were developed to predict the probability of 5-year DSS and OS after radical cystectomy. The C statistics were 77.8% and 77.3%, respectively, and exceeded the 2002 AJCC (72.0% and 70.3%, respectively). In the decision curve analyses, the nomograms including SIR demonstrated higher net benefit gains compared with the models without SIR. Conclusions: Cellular components of SIR have better prognostic values compared with acute-phase protein in patients undergoing radical cystectomy for bladder cancer.
引用
收藏
页码:461 / 467
页数:7
相关论文
共 50 条
  • [11] The prognostic value of the preoperative lung immune prognostic index in patients with urothelial bladder cancer undergoing radical cystectomy
    Koki Obayashi
    Jun Miki
    Wataru Fukuokaya
    Takafumi Yanagisawa
    Shoji Kimura
    Shunsuke Tsuzuki
    Takahiro Kimura
    Shin Egawa
    International Journal of Clinical Oncology, 2022, 27 : 396 - 402
  • [12] Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy
    Zareba, Piotr
    Patterson, Laurel
    Pandya, Rishikesh
    Margel, David
    Hotte, Sebastien J.
    Mukherjee, Som D.
    Elavathil, Leelamma
    Daya, Dean
    Shayegan, Bobby
    Pinthus, Jehonathan H.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (07) : 975 - 980
  • [13] NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder
    Potretzke, Aaron
    Hillman, Luke
    Wong, Kelvin
    Shi, Fangfang
    Brower, Ryan
    Mai, Stephanie
    Cetnar, Jeremy P.
    Abel, Edwin Jason
    Downs, Tracy M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (05) : 631 - 636
  • [14] Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy
    Wu, Jie
    Wen, Jun-Miao
    Wang, Yu-Chen
    Luo, Wen-Jie
    Wang, Qi-Feng
    Lv, Hong
    Dai, Bo
    Ye, Ding-Wei
    Su, Heng-Chuan
    Zhu, Yi-Ping
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [15] The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy
    Liu, Jianye
    Dai, Yingbo
    Zhou, Fangjian
    Long, Zhi
    Li, Yonghong
    Liu, Bin
    Xie, Dan
    Tang, Jin
    Tan, Jing
    Yao, Kun
    Zhang, Yichuan
    Tang, Yuxin
    He, Leye
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (11) : 484.e1 - 484.e8
  • [16] Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy
    Rajwa, P.
    Zyczkowski, M.
    Paradysz, A.
    Bujak, K.
    Bryniarski, P.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (10) : 3027 - 3037
  • [17] Prognostic significance of serum lactate dehydrogenase in patients undergoing radical cystectomy for bladder cancer
    Su, Shiqiang
    Liu, Lizhe
    Sun, Chao
    Yang, Lijun
    Nie, Yanhua
    Chen, Yan
    Zhang, Jin
    Li, Shen
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (11) : 852.e1 - 852.e9
  • [18] The Prognostic Value of Perioperative Platelet and Leukocyte Values in Patients Undergoing Radical Cystectomy: A Prospective Long-Term Cohort Study
    Pyrgidis, Nikolaos
    Schulz, Gerald B.
    Volz, Yannic
    Ebner, Benedikt
    Rodler, Severin
    Westhofen, Thilo
    Eismann, Lennert
    Marcon, Julian
    Stief, Christian G.
    Jokisch, Friedrich
    UROLOGIA INTERNATIONALIS, 2024, 108 (05) : 421 - 428
  • [19] Systematic Review and Meta-Analysis on the Role of Perioperative Blood Transfusion in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma
    Kochergin, Maxim
    Fahmy, Omar
    Esken, Lisa
    Goetze, Thorsten
    Xylinas, Evanguelos
    Stief, Christian G.
    Gakis, Georgios
    BLADDER CANCER, 2022, 8 (03) : 315 - 327
  • [20] Prognostic Value of NLR, PLR, SII, and dNLR in Urothelial Bladder Cancer Following Radical Cystectomy
    Salari, Abolfazl
    Ghahari, Mohammadreza
    Bitaraf, Masoud
    Fard, Elahe Samiee
    Haddad, Mojtaba
    Momeni, Seyed Ali
    Inanloo, Seyed Hassan
    Ghahari, Parichehr
    Mohamoud, Mohamoud Mohamed
    Mohamadzadeh, Maryam
    Nowroozi, Mohammad Reza
    Amini, Erfan
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)